Navigation Links
Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study
Date:7/21/2008

ts with an event on LDL-lowering treatment versus 355 on placebo; hazard ratio [HR] 0.96; 95% confidence interval [CI] 0.83 to 1.12). Nor was there a significant difference for the secondary endpoint of aortic valve disease events alone (308 versus 326; HR 0.97; 95% CI 0.83 to 1.14). The combination of simvastatin and ezetimibe did, however, produce a statistically significant 22% (95% CI 3% to 37%; p=0.02) proportional reduction in the secondary endpoint of atherosclerotic events alone: 148 (15.7%) in the simvastatin plus ezetimibe group versus 187 (20.1%) in the placebo group.

The study therapy was generally well tolerated, with no significant differences between the treatment groups in the proportions of patients who stopped taking study treatment (irrespective of whether it was active or placebo). In the subsidiary safety analyses, a total of 158 patients were recorded with a serious adverse event attributed to cancer. More of these events were observed among patients assigned the combination of simvastatin and ezetimibe than among those assigned placebo (93 [9.9%] versus 65 [7.0%]; unadjusted p=0.03), and there were also slightly more cancer deaths (39 [4.1%] versus 23 [2.5%]; unadjusted p=0.05). These apparent differences were not related to any particular type of cancer and did not become significantly larger with more prolonged treatment.

The observed differences in cancer in the SEAS study are based on small numbers and could have occurred as a result of chance. In order to assess their relevance, the SEAS data have been provided to an independent academic group for combined analysis with data on cancer from the two other large trials of simvastatin and ezetimibe, which are still in progress. The SHARP (Study of Heart and Renal Protection) study is a randomized placebo-controlled trial of simvastatin and ezetimibe in 9400 patients with chronic kidney disease. The IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial)
'/>"/>

SOURCE ;
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
5. Tapestry Reports Second Quarter 2007 Results
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- Research and Markets  has announced the addition ... report to their offering. ... hollow needle commonly used with a syringe to inject ... from it. A hypodermic needle is used for rapid ... be ingested. Hypodermic needles are broadly classified into non-safety ...
(Date:7/11/2014)... , July 11, 2014 ... at 4,396.20, down 0.52%, the Dow Jones Industrial Average finished ... closed at 1,964.68, down 0.41%. The losses were broad based ... negative. The S&P 500 Health Care Sector Index ended the ... 2.75% in the last one month. Investor-Edge has initiated coverage ...
(Date:7/11/2014)... , July 11, 2014  Veran Medical ... announced today the positive, cost-effective final results ... SPiNPerc™ procedure. The SPiNPerc endobronchial percutaneous biopsy ... percutaneous approach to biopsy when a traditional ... and physicians experience positive financial outcomes when ...
Breaking Medicine Technology:Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Veran Medical Publishes Lung Cancer Patient Management Study 2
... 4, 2011 Reportlinker.com announces that a new ... European Market for Cardiac Rhythm ... http://www.reportlinker.com/p0488652/European-Market-for-Cardiac-Rhythm-Management-Electrophysiology--Ablation-Devices-2011.html European Market ... 2011 (15 countries) In 2010, ...
... 2011 Reportlinker.com announces that a ... in its catalogue: ... – Bone Grafting and Hyaluronic Acid ... http://www.reportlinker.com/p0488653/European-Markets-for-Orthopedic-Biomaterials-2011-–-Bone-Grafting-and-Hyaluronic-Acid-Viscosupplementation-15-Countries.html The ...
Cached Medicine Technology:Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 2Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 3Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 4Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 5Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 6Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 7Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 8Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 9Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 10Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 11Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 12Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 13Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 14Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 15Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 16Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 17Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 18Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 19Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 20Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 21Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 2Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 3Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 4Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 5Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 6Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 7Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 8Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 9Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 10Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 11Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 12Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 13Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 14Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 15Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 16
(Date:7/13/2014)... By Serena Gordon ... -- A new type of sensor for people with ... body using saliva instead of blood, researchers report. Scientists ... successfully tested it using artificial saliva. It uses light, metal ... blood sugar. "Everybody knows that diabetics have to prick ...
(Date:7/13/2014)... Recently, 2014QuinceaneraDresses.com, the distinguished special occasion dress manufacturer ... gorgeous Quinceanera dresses . , In ... outfits is huge. Therefore, 2014QuinceaneraDresses.com is striving to ... released dresses are made according to the latest ... , It is worthy of mention that ...
(Date:7/13/2014)... 13, 2014 Epidemiologists forecast an increase ... 6MM, from 8,062 diagnosed incident cases in 2013 to ... Growth Rate (AGR) of 4.35%, during the forecast period. ... of diagnosed incident cases of aGVHD in the 6MM, ... the lowest number of diagnosed incident cases of aGVHD, ...
(Date:7/13/2014)... 13, 2014 Wright & Schulte LLC ... been scheduled in July of 2015, in U.S. District ... are in the discovery process in the South ... is presiding over the multidistrict litigation (MDL). The complaints ... of individuals who allege that they took the statin ...
(Date:7/13/2014)... 2014 Hope Palliative & Hospice Care announced ... group at the Tamarack Senior Living Community in Palatine, IL. ... A.M. on the 3rd Wednesdays of every month. This ... Tamarack Community located at 55 S. Greeley St. Palatine, IL ... there is no cost for the group. , “A ...
Breaking Medicine News(10 mins):Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:Hope Hospice Announces Grief Support Group at the Tamarack Senior Living Community 2
... drug to the usual three-drug HIV treatment regimen is not ... the HIV load// or the drug resistance, the new study ... JAMA, a theme issue on HIV/AIDS. ,Roy M. ... New York, presented the findings of the study today at ...
... used HIV treatments, researchers found one triple-drug therapy was ... the blood when used as a first-line treatment. Results ... among three different therapies the optimal approach for patients ... reported at the XVI International AIDS Conference (AIDS 2006). ...
... new study published in the September 15, 2006 issue ... Society, says that African-Americans are least likely to// ask ... says that the level of interest displayed by Caucasian ... This fact may lead to the African-Americans making less-informed ...
... has said that better quality drugs and child medication ... ,Speaking to Agence France-Presse (AFP) ... in Toronto he said, "We definitely need to improve ... talking to pharmaceuticals. We definitely want to buy second-line ...
... radical changes in business with tangible growth in Asian countries, ... of a jet setting pace, so much a part of ... a demographic crisis, with a rampant spread of mental health ... palpable, and is attributed to the high stress in the ...
... in on a weakened scout cell, which is known to ... out that cancer in some of the transplant patients shows ... for the immune system. Researchers are optimistic that by ... find ways to prevent the onset of cancer. The reason ...
Cached Medicine News:Health News:Four-Drug AIDS Treatment Regimen Deemed Of No Use 2Health News:Study Compares First-Line Drug Therapies For Treating HIV 2Health News:Study Compares First-Line Drug Therapies For Treating HIV 3Health News:Study Compares First-Line Drug Therapies For Treating HIV 4Health News:African-Americans Pose Less Questions To Treating Doctors 2Health News:Need for Newer AIDS Drugs In China 2
Smaller diameter wire probes & olive shape tips provide easier insertion through the lacrimal sac, 35cm (14 in) long, ID- .30mm (.012in); OD- .64mm (.025 in). S.S. Probes: .40mm x 11cm (27 G x 4 1/4...
...
Pre-set guard for precise depth incision, bi-directional blade can cut left or right. 250 micron....
Universal, clear, lightweight plastic with smooth edges & ventilation holes for patient comfort...
Medicine Products: